The company's pipeline includes three agents: JAG101, a gene therapy treatment in development for galactosemia; JAG201, a gene therapy treatment in development for a specific genetic cause of autism spectrum disorder; and JAG301, a gene therapy treatment in development for type 1 diabetes.

Jaguar's subsidiary, Axovia Therapeutics, is also advancing AXV101, a gene therapy treatment for subset of Bardet-Biedl syndrome (BBS), BBS1.

The series B funding was co-led by Eli Lilly and Deerfield Management. Additional investors include ARCH Venture Fund XI, the Goldman Sachs fund, and Nolan Capital.

Jaguar Gene Therapy launches, targeting rare genetic diseases
Jaguar Gene Therapy has launched after being in stealth mode with the goal of accelerating the development, manufacturing, and commercialization of novel...